# Thermo Fisher Scientific

> Thermo Fisher Scientific is a VC fund backing Health Diagnostics. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Waltham, United States
- Total investments: 4
- Last investment: Dec 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/thermo-fisher-scientific
- X (Twitter): http://twitter.com/ThermoFisher
- Website: http://www.thermofisher.com
- Facebook: https://www.facebook.com/thermoscientific

Thermo Fisher Scientific is a VC fund in Waltham focused on Health Diagnostics and Health Care. Thermo Fisher Scientific is the world leader in serving science, with annual revenue exceeding $30 billion. Its mission is to enable our customers to make the world healthier, cleaner, and safer. Whether its customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, orincreasing productivity in their laboratories, they are here to support them. Its global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

## Contacts

5 contacts available for Thermo Fisher Scientific. Shizune tracks 15 team members at Thermo Fisher Scientific. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/thermo-fisher-scientific?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Diagnostics | 4 | 100% |
| Health Care | 3 | 75% |
| Biotechnology | 3 | 75% |
| Medical | 2 | 50% |
| Biopharma | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series D | 1 | 25% |
| Corporate Round | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 25% |
| Israel | 1 | 25% |
| Belgium | 1 | 25% |
| United States | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gianluca Pettiti | Executive Vice President | 1 | https://shizune.co/investors/profile/gianluca-pettiti |
| Marc Casper | President | 1 | https://shizune.co/investors/profile/marc-n-casper |
| Marc Casper | President | 1 | https://shizune.co/investors/profile/marc-n-casper-fd2d |
| Alan J. Malus | President of the New Analytical Technologies Group | 0 | https://shizune.co/investors/profile/alan-j-malus |
| Barbara A. Paldus | VP/GM Measurement and Control | 2 | https://shizune.co/investors/profile/barbara-a-paldus |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| miDiagnostics | miDiagnostics is developing a new generation of disposable tests that require only drops of blood and allow detection of cells, proteins, nucleic acids, and/or small molecules. | $31.5M | Series D | Dec 04, 2024 |  |
| CytoReason | CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology. | $80M | Series B | Jul 17, 2024 |  |
| Ionpath | Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health. |  | Corporate Round | May 11, 2022 |  |
| WuXi Diagnostics | WuXi Diagnostics builds an innovative model that enables diagnostic product innovation, generates clinical insights, and benefits the health of mankind through precision diagnosis and treatment. | $150M | Series B | Feb 23, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 1 deal together
- [Alychlo](https://shizune.co/investors/profile/alychlo) — VC Fund, 1 deal together
- [Astarc Ventures](https://shizune.co/investors/profile/astarcventures) — VC Fund, 1 deal together
- [CCBI Tech Venture](https://shizune.co/investors/profile/ccbi-tech-venture) — VC Fund, 1 deal together
- [M&G Investments](https://shizune.co/investors/profile/m-g-investments-2f25) — VC Fund, 1 deal together
- [NVIDIA](https://shizune.co/investors/profile/nvidia) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Thermo Fisher Scientific invest in?

Thermo Fisher Scientific invests primarily in Health Diagnostics, Health Care and Biotechnology startups, most often at Series B and Series D stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Thermo Fisher Scientific?

Public channels for Thermo Fisher Scientific include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Thermo Fisher Scientific?

The team at Thermo Fisher Scientific includes Gianluca Pettiti (Executive Vice President), Marc Casper (President) and Marc Casper (President), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co